The Impact of FLT3 Inhibitors for the Treatment of AML
Meir Wetzler, MD, from Roswell Park Cancer Institute, discusses the potential impact of FLT3 inhibitors for the treatment of patients with acute myeloid leukemia.
Clinical Pearls
Meir Wetzler, MD, chief, Leukemia Section, Department of Medicine, Professor of Medicine, Department of Medicine, Roswell Park Cancer Institute, discusses the potential impact of FLT3 inhibitors for the treatment of patients with acute myeloid leukemia.
- In CML, initially only imatinib was available in the frontline, but now nilotinib and dasatinib are approved.
- FLT3 inhibitors did not show significant efficacy in the relapsed/refractory setting of AML, so they were evaluated in the frontline.
Recent Videos
Related Content
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Article
Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
